Clinical Trials Logo

Unrecognized Condition clinical trials

View clinical trials related to Unrecognized Condition.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06339996 Recruiting - Clinical trials for Unrecognized Condition

Male Supplements for Sperm Quality and Aging

Start date: March 26, 2024
Phase: N/A
Study type: Interventional

This study investigates the effects of a new supplement on sperm quality in men with poor sperm quality. Fifty patients will receive the supplement for three months, followed by semen analysis and assessment of sperm aging and mitochondrial function. Changes in sexual function and aging symptoms will also be evaluated.

NCT ID: NCT05873075 Recruiting - Clinical trials for Unrecognized Condition

Intravascular Laser Irradiation of Blood Use in Poor Ovarian Responders

Start date: April 27, 2023
Phase: N/A
Study type: Interventional

The aim of this study was to investigate the effects of intravascular laser irradiation of blood on outcomes of in vitro fertilization cycles in poor ovarian responders.

NCT ID: NCT05478616 Recruiting - Clinical trials for Unrecognized Condition

Expression of Endometrium During Window of Implantation

Start date: July 1, 2022
Phase:
Study type: Observational

The aim of this study was to investigate the expression of endometrium during window of implantation between natural cycles and artificial cycles.

NCT ID: NCT05319132 Recruiting - Clinical trials for Unrecognized Condition

Evaluate DF-003 in ex Vivo Assays Using Peripheral Blood Mononuclear Cell From Subjects With ROSAH Syndrome

ROSAH
Start date: September 6, 2022
Phase:
Study type: Observational

Alpha-1 kinase (ALPK1) has been reported as a potential causative gene for ROSAH Syndrome. Genetic variants including T237M have been found in ROSAH Syndrome patients. Our in-house study has found that T237M mutation leads to hyperactivity of ALPK1, which may be the cause of the inflammatory syndromes found in ROSAH Syndrome patients. We hypothesize that T237M mutation ALPK1 cause ROSAH Syndrome and an ALPK1 inhibitor can be a potential therapy for treating this disease. To test our hypothesis, we designed an experiment in which ex vivo peripheral blood mononuclear cells (PBMCs) from ROSAH Syndrome patients will be exposed to a potent ALPK1 inhibitor (DF-003) or placebo. We expect to see downregulation of activated inflammatory genes, chemokine/cytokines and acute phase proteins in the ROSAH Syndrome patient samples that are exposed DF-003.

NCT ID: NCT04931316 Recruiting - Clinical trials for Unrecognized Condition

Incidence and Management of Ocular Hypertension Following Deep Anterior Lamellar Keratoplasty

Dalk
Start date: March 15, 2021
Phase:
Study type: Observational

This is a retrospective case series study that included patients who performed deep anterior lamellar keratoplasty and presented with elevated intraocular pressure during follow up.